ARA-290 (Cibinetide) — the tissue-repair receptor in research

ARA-290, also known as cibinetide, is a synthetic peptide built from 11 amino acids, designed on the basis of a fragment of the erythropoietin (EPO) molecule. It reproduces the region corresponding to the so-called helix B of the native protein — that is, the part of the EPO surface that, in research, is associated with its tissue-protective action rather than with red blood cell production. It can be thought of as a "Lego brick" taken out of a larger protein: a single fragment that retains one selected function of the original. It is precisely this selectivity that made ARA-290 a subject of interest in preclinical research on tissue repair and the regulation of inflammation.

Mechanism in brief

The "lock and key" principle describes well what sets ARA-290 apart. Native erythropoietin fits the classical, homodimeric EPO receptor (EPOR) — the one that in the body triggers the hematopoietic pathway and erythrocyte production. ARA-290 was designed so that it does not fit that "lock." Instead, in the literature it is described as a selective agonist of a distinct receptor complex — a heterocomplex composed of an EPOR subunit and the beta-common receptor (CD131). This complex is sometimes called the innate repair receptor (IRR). The absence of erythropoietic pathway activation is a key feature in research, because it allows the repair potential to be separated from the effect on erythrocyte count. After the peptide binds, the intracellular JAK2/STAT3 and PI3K/Akt signaling pathways are analyzed, which are associated with limiting apoptosis and modulating the inflammatory response.

What is under study

The areas below refer exclusively to laboratory models and preclinical data — they do not describe action in humans. Each of them is assigned to the model in which it was analyzed.

• Tissue protection and repair (animal models). In models of ischemia-reperfusion injury (including the heart and kidneys), the role of IRR activation and the PI3K/Akt pathway was studied in the context of limiting cell death. This is an area of research into cytoprotection mechanisms.
• Damping of pro-inflammatory signaling (animal models, in vitro). The effect of IRR agonism on mediators of the inflammatory reaction was analyzed in cell lines and in animals — in the context of switching the immune response from a pro-inflammatory phase toward a reparative phase.
• Small-fiber neuropathy (animal models, limited human data). ARA-290 was studied in neuropathy models in the context of the sensory function of nerve fibers and the density of nerve endings in the skin. Early-phase clinical studies were also conducted (including in the context of small-fiber neuropathy accompanying sarcoidosis) — this, however, is still a limited set of human data.
• Neuroinflammation (animal models). In neuroinflammatory models, the involvement of the IRR pathway in regulating the local inflammatory response of nervous tissue was analyzed.

Origin and historical context

The concept of ARA-290 grows out of the observation that erythropoietin — beyond its hematopoietic function — shows, in research, protective properties toward tissues. Work on separating these two roles, so as to obtain a "repair" molecule devoid of any effect on hematocrit, was carried out by researchers associated with this field, including Michael Brines and Anthony Cerami. The further development of cibinetide as a research candidate is associated with Araim Pharmaceuticals. The name innate repair receptor itself appeared precisely in the context of describing the EPOR/CD131 heterocomplex as a molecular target for tissue-protective peptides.

Research specification

ARA-290 is supplied for laboratory use usually in the form of a lyophilisate (powder after lyophilization), stored under conditions that protect the peptide from moisture and degradation. The quality standard for research material is purity confirmed by HPLC (high-performance liquid chromatography) — this parameter describes the homogeneity of the preparation, not any biological action. Detailed physicochemical data, the CAS number, and information on safe handling of the substance can be found in the documentation — see the safety data sheets.

Evidence level

Evidence concerning ARA-290 comes primarily from in vitro studies (cell lines) and animal models. There is a limited set of data from early-phase clinical studies, but it does not allow general conclusions to be drawn, and cibinetide remains a research compound — it is not an approved medicinal product. Many of the described mechanisms (IRR agonism, the JAK2/STAT3 and PI3K/Akt pathways) are working hypotheses requiring further verification. Every result should be read in the context of the specific model in which it was obtained, and treated as a starting point for further research.

For research purposes only. Not for consumption by humans or animals.